Please login to the form below

Not currently logged in
Email:
Password:

cilengitide

This page shows the latest cilengitide news and features for those working in and with pharma, biotech and healthcare.

Glioblastomas - a personalised future?

Glioblastomas - a personalised future?

Another angiogenesis inhibitor, cilengitide, is in phase 3 development in Germany and the US in combination with temozolomide and radiation therapy, in newly diagnosed patients, and phase 2 in Germany in

Latest news

  • Merck KGaA forges clinical alliance with Quintiles Merck KGaA forges clinical alliance with Quintiles

    Moreover It has suffered a number of late-stage pipeline disappointments of late, including failures for brain and lung cancer prospect cilengitide and cladribine for multiple sclerosis.

  • Merck KGaA to meet 2014 financial targets one year early Merck KGaA to meet 2014 financial targets one year early

    and recently-licensed MS drug Tcelna (imilecleucel-T) following the decision to drop brain and lung cancer prospect cilengitide from development in the first quarter.

  • Late-stage failure for Merck’s cilengitide in brain cancer Late-stage failure for Merck’s cilengitide in brain cancer

    Merck KGaA has endured a pipeline setback with disappointing phase III results for its investigational brain cancer drug cilengitide. ... However, this has not proved the case for cilengitide in Merck's phase III CENTRIC (a) trial.

  • Cilengitide could promote tumour growth

    It was suggested that this could be a previously unknown characteristic of drugs similar to cilengitide. ... Results of the cilengitide study were published in the March 22 online issue of Nature Medicine.

  • Back on track

    Merck's Cilengitide has demonstrated promising results in a phase I trial and is currently undergoing phase II studies in the US. ... Cilengitide is a vitronectin (avï 3) inhibitor designed to inhibit angiogenesis.

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics